Gan & Lee Pharmaceuticals.: Legal Opinion of Zhong Lun Law Firm on the Repurchase and Cancellation of Restricted Stocks under the 2022 Restricted Stock Incentive Plan of Gan & Lee Pharmaceuticals Co., Ltd. in Beijing
Announcement on the completion of the implementation of the plan for senior management to increase their shareholding in the company.
Announcement of Annual Equity Distribution Implementation in 2023
Announcement on the completion of registration for the 2024 Restricted Stock Incentive Plan
Notice to creditors on the repurchase and cancellation of some restricted shares
Announcement on Adjusting the List of Incentive Targets and the Amount Granted for the Company's 2024 Restricted Stock Incentive Plan
Announcement on granting restricted shares to incentive recipients of the 2024 Restricted Stock Incentive Plan
Legal Opinion of Beijing Zhonglun Law Firm on the adjustments and grants related to Ganli Pharmaceutical Co., Ltd.'s 2024 Restricted Stock Incentive Plan
2024 Restricted Stock Incentive Plan Incentive Recipients List (Grant Date)
Verification opinions on matters relating to granting restricted shares to incentive recipients of the Company's 2024 Restricted Stock Incentive Plan
Announcement on plans for senior management to increase their shareholding in the company
An indicative announcement on the 2022 Restricted Stock Incentive Plan's first lifting of sales restrictions and the release of sales restrictions and listing circulation
Legal Opinion of Beijing Zhonglun Law Firm on Ganli Pharmaceutical Co., Ltd.'s 2022 Restricted Stock Incentive Plan to lift the sales restriction period, release the sales restriction conditions, and repurchase and cancel some restricted stocks
Announcement on the pledge of some shares by shareholders holding 5% or more of the shares
Announcement on the achievements of the company's 2022 restricted stock incentive plan for the first time to lift the sales restriction period and lift the sales restriction conditions
Legal Opinion of Beijing Zhonglun Law Firm on Ganli Pharmaceutical Co., Ltd.'s 2022 Restricted Stock Incentive Plan to lift the sales restriction period, release the sales restriction conditions, and repurchase and cancel some restricted stocks
Announcement on the repurchase and cancellation of some restricted shares in the 2022 Restricted Stock Incentive Plan
Announcement on the company's 2023 profit distribution plan
Self-inspection report on the 2024 Restricted Stock Incentive Plan insider information informants and incentive recipients trading the company's stock
An indicative announcement on changes in the equity of shareholders holding 5% or more of the shares to 1%
No Data